@article {CAMPODONICO2381, author = {FABIO CAMPODONICO and GIORGIO CANEPA and GIACOMO CAPPONI and LUIGI BOZZO and MASSIMO MAFFEZZINI}, title = {Intravesical Gemcitabine in Recurrent Superficial Bladder Carcinoma: Preliminary Results on Ablative Efficacy and Tolerability}, volume = {25}, number = {3C}, pages = {2381--2384}, year = {2005}, publisher = {International Institute of Anticancer Research}, abstract = {Background: The ablative potential and toxicity of gemcitabine, administered intravesically in low stage and grade superficial transitional cell carcinoma (TCC), were evaluated. Patients and Methods: Patients with a history of recurrent Ta-T1, G1-G2 bladder TCC were considered eligible for the study. Gemcitabine was administered intravesically at 40 mg/mL concentration (2000 mg in 50 ml saline) in one weekly instillation for 4 consecutive weeks. Fifteen days after the last instillation, patients were submitted to transurethral resection (TUR). Results: Twenty-six patients were evaluable for toxicity, and 20 were evaluable for response, 6 patients being excluded due to toxicity. A complete response was achieved by 10 out of 20 patients (50\%), whereas no response was documented in the remainder. Toxicity leading to treatment interruption was grade 3 in 1 patient and grade 2 in 5 patients. Conclusion: Intravesical gemcitabine administered at 40 mg/mL showed the capability of ablating small volume, superficial TCC in 50\% of the population under study, with acceptable tolerability.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/25/3C/2381}, eprint = {https://ar.iiarjournals.org/content/25/3C/2381.full.pdf}, journal = {Anticancer Research} }